ChemicalBook > CAS DataBase List > Blosozumab
Blosozumab
- Product Name
- Blosozumab
- CAS No.
- 1132758-87-2
- Chemical Name
- Blosozumab
- Synonyms
- Blosozumab;Blosozumab (anti-SOST);Research Grade Blosozumab;Research Grade Blosozumab(DHJ48702)
- CBNumber
- CB08080837
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Blosozumab Property
- form
- Liquid
- color
- Colorless to light yellow
More
Less
Blosozumab Chemical Properties,Usage,Production
Uses
Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis[1][2].
in vivo
Blosozumab (1-100 mg/kg, i.v.) shows effects of hyperostosis in rats[1].
| Animal Model: | Sprague-Dawley rats [2] |
| Dosage: | 1, 10, and 100 mg/kg |
| Administration: | Intravenous injection (i.v.), once every 3 days (5-week study) or once weekly (6-month study) |
| Result: | Observed the bone anabolic effects. Showed significant bleeding and morbidity at 100 mg/kg. Decreases in the numbers of platelets. Increased number of bone marrow megakaryocytes at 100 mg/kg. |
References
[1] Robert R Recker, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015 Feb;30(2):216-24. DOI:10.1002/jbmr.2351
[2] Daniel G Rudmann, et al. Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci. 2012 Feb;125(2):586-94. DOI:10.1093/toxsci/kfr318
Blosozumab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Blosozumab Suppliers
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Country
- United States
- ProdList
- 12952
- Advantage
- 65
- Tel
- tp@aladdinsci.com
- Country
- United States
- ProdList
- 57505
- Advantage
- 58
1132758-87-2, BlosozumabRelated Search:
Cetrelimab
Teneliximab
Elezanumab
Ixekizumab
CNTO 148
ofatumumab
Nidanilimab
Tilvestamab
Omburtamab
Tislelizumab